Crossmark

Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment

Crossref DOI link: https://doi.org/10.1186/s12936-019-3032-3

Published Online: 2019-12-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Omondi, Protus

Burugu, Marion

Matoke-Muhia, Damaris

Too, Edwin

Nambati, Eva A.

Chege, William

Musyoka, Kelvin B.

Thiongo, Kelvin

Otinga, Maureen

Muregi, Francis

Kimani, Francis https://orcid.org/0000-0001-5150-2068
Funding

Funding for this research was provided by:

World Bank Group

Government of the Republic of Kenya (IRG SERU 3236)
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-04
More Information

Article History

Received: 10 June 2019

Accepted: 24 November 2019

First Online: 4 December 2019

Ethics approval and consent to participate

: The study was part of a bigger study (Protocol SSC 2276/3236) in the Kenya medical research institute entitled “Efficacy of artemisinin-based combination therapy (ACT) in Kenya.” The present study (Protocol SSC 3699) was approved on 5th September 2018 by the scientific review unit of the Kenya Medical Research Institute.

: The consent for publication was granted by the KEMRI publications review unit for the Director General KEMRI.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below